www.fiercebiotech.com/biotech/...s-arch-rival-eylea-ph3-trials
Novartis has been losing ground in the age-related macular degeneration (AMD) market, but a pair of positive phase 3 trials for new drug brolucizumab (aka RTH258) suggests a comeback could be on the cards.
AMD affects up to 25 million people worldwide and is the leading cause of early blindness in the industrialized world, and for some years Novartis' VEGF inhibitor Lucentis (ranibizumab) was the leading treatment for the wet or 'neovascular' form of the disease.
Latterly however the drugmaker, along with partner Roche, has been in a toe-to-toe battle with Bayer and Regeneron, whose rival VEGF/PIGF inhibitor Eylea (aflibercept) has been in the ascendency despite Lucentis' first-to-market advantage.
Novartis has been losing ground in the age-related macular degeneration (AMD) market, but a pair of positive phase 3 trials for new drug brolucizumab (aka RTH258) suggests a comeback could be on the cards.
AMD affects up to 25 million people worldwide and is the leading cause of early blindness in the industrialized world, and for some years Novartis' VEGF inhibitor Lucentis (ranibizumab) was the leading treatment for the wet or 'neovascular' form of the disease.
Latterly however the drugmaker, along with partner Roche, has been in a toe-to-toe battle with Bayer and Regeneron, whose rival VEGF/PIGF inhibitor Eylea (aflibercept) has been in the ascendency despite Lucentis' first-to-market advantage.